JP7677628B2 - 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法 - Google Patents

肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法 Download PDF

Info

Publication number
JP7677628B2
JP7677628B2 JP2021511621A JP2021511621A JP7677628B2 JP 7677628 B2 JP7677628 B2 JP 7677628B2 JP 2021511621 A JP2021511621 A JP 2021511621A JP 2021511621 A JP2021511621 A JP 2021511621A JP 7677628 B2 JP7677628 B2 JP 7677628B2
Authority
JP
Japan
Prior art keywords
kit
sequence
seq
antisense oligomer
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021511621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534799A5 (https=
JP2021534799A (ja
Inventor
ピー クルース グレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University filed Critical North Carolina State University
Publication of JP2021534799A publication Critical patent/JP2021534799A/ja
Publication of JP2021534799A5 publication Critical patent/JP2021534799A5/ja
Priority to JP2025071212A priority Critical patent/JP2025121926A/ja
Application granted granted Critical
Publication of JP7677628B2 publication Critical patent/JP7677628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2021511621A 2018-08-27 2019-08-27 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法 Active JP7677628B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025071212A JP2025121926A (ja) 2018-08-27 2025-04-23 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723326P 2018-08-27 2018-08-27
US62/723,326 2018-08-27
PCT/US2019/048400 WO2020046985A1 (en) 2018-08-27 2019-08-27 Targeting kit with splice switching oligonucleotides to induce apoptosis of mast cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025071212A Division JP2025121926A (ja) 2018-08-27 2025-04-23 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法

Publications (3)

Publication Number Publication Date
JP2021534799A JP2021534799A (ja) 2021-12-16
JP2021534799A5 JP2021534799A5 (https=) 2022-09-05
JP7677628B2 true JP7677628B2 (ja) 2025-05-15

Family

ID=69644689

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511621A Active JP7677628B2 (ja) 2018-08-27 2019-08-27 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法
JP2025071212A Pending JP2025121926A (ja) 2018-08-27 2025-04-23 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025071212A Pending JP2025121926A (ja) 2018-08-27 2025-04-23 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法

Country Status (6)

Country Link
US (1) US20210363531A1 (https=)
EP (1) EP3844278A4 (https=)
JP (2) JP7677628B2 (https=)
CN (1) CN112771162B (https=)
CA (1) CA3110353A1 (https=)
WO (1) WO2020046985A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136435A1 (en) 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
WO2025231071A1 (en) * 2024-05-01 2025-11-06 Beam Therapeutics Inc. Compositions and methods for cell conditioning
CN121177520B (zh) * 2025-11-24 2026-03-27 首都医科大学附属北京口腔医院 含有c-Kit的生物制品及其在调控牙源性器官组织发育中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002507186A (ja) 1991-05-09 2002-03-05 テンプル ユニバーシティ−オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション ｃ−ｋｉｔプロト−オンコ遺伝子に対するアンチセンスオリゴヌクレオチドおよびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0423980T3 (da) * 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
US5989849A (en) * 1991-05-09 1999-11-23 Temple University Of The Commonwealth System Of Higher Education Antisense of oligonucleotides to c-kit proto-oncogene and in vitro methods
US5641625A (en) * 1992-05-22 1997-06-24 Isis Pharmaceuticals, Inc. Cleaving double-stranded DNA with peptide nucleic acids
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1539689A2 (en) * 2002-07-19 2005-06-15 Pharmacia Corporation Antisense modulation of endothelial lipase expression
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
EP2933332A1 (en) * 2004-06-28 2015-10-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8501703B2 (en) * 2005-08-30 2013-08-06 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
WO2015168108A2 (en) * 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
EP2985343A1 (en) * 2014-08-11 2016-02-17 Karlsruher Institut für Technologie In vitro-co-culturesystem

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002507186A (ja) 1991-05-09 2002-03-05 テンプル ユニバーシティ−オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション ｃ−ｋｉｔプロト−オンコ遺伝子に対するアンチセンスオリゴヌクレオチドおよびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer research，2001年，Vol.61，p.2200-2206
Oligonucleotide-based drugs and therapeutics : Preclinical and Clinical Considerations for development, Splice-switching oligonucleotides，2018年，p.445-489，Doi:10.1002/9781119070153.ch17

Also Published As

Publication number Publication date
JP2025121926A (ja) 2025-08-20
CA3110353A1 (en) 2020-03-05
EP3844278A1 (en) 2021-07-07
CN112771162B (zh) 2026-02-13
WO2020046985A1 (en) 2020-03-05
EP3844278A4 (en) 2022-05-25
JP2021534799A (ja) 2021-12-16
CN112771162A (zh) 2021-05-07
US20210363531A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
JP6414886B2 (ja) 抗癌治療に用いられる長鎖非コードｒｎａ
JP6091752B2 (ja) Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
JP2025121926A (ja) 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法
JP7536049B2 (ja) 血管新生障害の処置
EP2146736B1 (en) Srpin340 as modulator of vegf splicing and anti-angiogenic agents
CN104583406A (zh) 治疗kras相关疾病的有机组合物
US20230383292A1 (en) Targeting xist and rna methylation for x reactivation therapy
KR20210110310A (ko) 올리고머 핵산 분자 및 그의 이용
EP3661924A1 (en) Compounds, compositionals, and methods for treating t-cell acute lymphoblastic leukemia
US20220380777A1 (en) Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases
US20110082185A1 (en) Cancer-testis gene silencing agents and uses thereof
JP2020521743A (ja) 癌を処置するためのアンチセンス療法
Miele et al. Downregulation of miR‐326 and its host gene β‐arrestin1 induces pro‐survival activity of E2F1 and promotes medulloblastoma growth
JP2017511302A (ja) Ｋ−Ｒａｓをサイレンシングする非対称干渉ＲＮＡ組成物およびその使用方法
US20230287427A1 (en) Inhibition of lncExACT1 to Treat Heart Disease
JP2007530431A (ja) 膵臓癌を治療するための組成物および方法
Shrestha et al. Angiotensin II receptor type 1 blockade regulates Klotho expression to induce TSC2-deficient cell death
CN105779576B (zh) 人tnfrsf12a基因的用途及其相关药物
CN113508175A (zh) 用于治疗癌症的组合物和方法
JP2006180710A (ja) Ｋｌｆ５遺伝子の発現を抑制するｒｎａ
US10166251B2 (en) STAT5a and its functional tumor suppressor analogs for treatment of malignancies expressing NPM/ALK and other oncogenic kinases
US20210261966A1 (en) TREATMENT OF CARDIOMYOPATHY THROUGH MODULATION OF HYPOXIA-INDUCED eRNA ACTIVITY
EP4299742A1 (en) Combination therapy for melanoma
JP2013039036A (ja) ＨＩＦ−２αの発現を抑制する核酸
US20220259596A1 (en) Inhibitors of microRNA 451a for Treatment of Endometriosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220826

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250423

R150 Certificate of patent or registration of utility model

Ref document number: 7677628

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150